Health Plans
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

New Democrat Coalition Sets 2012 Healthcare Priorities

Margaret Dick Tocknell, for HealthLeaders Media, December 14, 2011

2.Facilitate cooperation between the public and private sectors to promote successful implementation of healthcare delivery models that increase efficiency and improve patient care.

  • Facilitate participation in new Medicare delivery models by allowing successful multi-payer demonstrations to expand to traditional Medicare fee-for-service beneficiaries.
  • Enable private payers to invest in infrastructure development for smaller practices that want to develop or participate in innovative care delivery models.
  • Improve consistency in data collection and analysis across Medicare shared savings programs.
  • Consolidate elements of various shared savings programs such as quality reporting systems and technical assistance to conserve resources.
  • While protecting patient privacy, increase de-identified data sharing across the Medicare program to allow for more accurate comparisons of spending and outcomes.
  • Invest in enhanced research, better care coordination, and disease management through continued support for providers and third-party payers to reduce the burden of ICD-10 conversion.

3.Modernize the FDA approval process to foster innovation, growth through competition, and timely patient access to new treatments and technologies.

  • Ensure that the FDA has the funding and Congressional support to carry out its mission.
  • Ensure that the FDA uses its funding more efficiently to meet its performance targets and keeps a concentrated, top-to-bottom focus on innovation.
  • Engage industry stakeholders to better assess the cost of moving products through the FDA approval process.
  • Build on the successful practices demonstrated through FDA's 510(k) approval process that allow safe and effective technology and innovations to get to market in the most efficient way possible.
  • Address uncertainties in the FDA approval process by setting explicit and transparent guidelines for drug and device manufacturers.
  • Foster an open dialogue between regulators and the private sector to reduce administrative burdens on both sides.
1 | 2 | 3 | 4

Comments are moderated. Please be patient.